GU Cancers 2025 | EXTEND: Phase II trial of MDT plus ADT in oligometastatic prostate cancer

Alexander Sherry • 13 Feb 2025

GU Cancers 2025

Alexander Sherry, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the primary results of the Phase II EXTEND trial (NCT03599765), which evaluated metastasis-directed therapy (MDT) plus continuous androgen deprivation therapy (ADT) in oligometastatic prostate cancer. MDT with ADT improved progression-free survival, radiologic progression, and castration-resistance-free survival. Immune analysis also revealed MDT-induced TCR repertoire modulation, linked to longer progression-free survival and validated in the ORIOLE trial (NCT02680587). This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.